Login
Regeneron Pharmaceuticals NASDAQ: REGN
Regeneron's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema and Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents
| Name | Regeneron Pharmaceuticals |
| Ticker | REGN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
461.57
429.78 / 658.21 |
| Momentum | Weak Down |
| Market cap | 49 B |
| 1Y Total Return |
-6.65%
Weak |
| 1Y Volatility |
40.76%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Regeneron's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema and Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents
Details
| Ticker | REGN |
| Name | Regeneron Pharmaceuticals |
| ISIN | US75886F1075 |
| CUSIP | 75886F107 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 3/5/21
| Close Price | 461.57 |
| 52W Low/High | 429.78 / 658.21 |
| Market cap | 49 B |
| 1Y Total Return |
-6.65%
Weak |
| 1Y Volatility |
40.76%
Low Risk |
| Beta | 0.27 |
| PE (trailing) |
15.12
Low |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 41.3% |
| Cash from Op. / Cur. Liabilities | 0.97 |
| Diluted Earnings / Share | 30.52 |
| ROE | 31.8% |
| ROIC | 29.1% |
| Price / Revenue | 6.3 |
| Price / Book | 4.8 |
| Price / CF | 20.3 |
| Current Ratio | 3.6 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.24 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
8,497
|
6,558
|
5,146
|
5,872
|
4,860
|
4,104
|
|
| Gross Profit |
7,377
|
5,793
|
4,728
|
5,475
|
4,561
|
3,711
|
|
| R&D |
2,735
|
2,450
|
1,469
|
2,075
|
2,052
|
1,621
|
|
| EBITDA |
4,103
|
2,670
|
2,730
|
2,249
|
1,442
|
1,314
|
|
| Operating Income |
3,577
|
2,210
|
2,534
|
2,080
|
1,331
|
1,252
|
|
| Net Income exc. Extra |
3,513
|
2,116
|
2,444
|
1,199
|
896
|
636
|
|
| per Share | |||||||
| Diluted avg Shares |
115
|
115
|
115
|
116
|
116
|
115
|
|
| EPS exc. Extra |
30.52
|
18.46
|
21.29
|
10.34
|
7.70
|
5.52
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
17,163
|
14,805
|
11,735
|
8,764
|
6,973
|
5,609
|
|
| Cash, Eq & Invt ShortTerm |
3,587
|
3,214
|
2,810
|
1,410
|
1,039
|
1,045
|
|
| Total Current Assets |
9,779
|
7,689
|
6,448
|
4,335
|
3,180
|
2,915
|
|
| Total Non-Current Assets |
7,384
|
7,116
|
5,287
|
4,429
|
3,793
|
2,694
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
6,138
|
3,716
|
2,977
|
2,620
|
2,524
|
1,954
|
|
| Total Current Liabilities |
2,697
|
2,097
|
1,443
|
1,136
|
1,241
|
811
|
|
| Long Term Debt |
3,441
|
1,619
|
1,534
|
1,485
|
1,283
|
1,143
|
|
| Shareholder equity |
11,025
|
11,090
|
8,757
|
6,144
|
4,449
|
3,655
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
2,618
|
2,430
|
2,195
|
1,307
|
1,486
|
1,331
|
|
| Depreciation |
236
|
210
|
148
|
146
|
105
|
75
|
|
| Cash from Investing |
-71
|
-2,028
|
-1,463
|
-1,005
|
-1,047
|
-908
|
|
| Capex |
615
|
430
|
383
|
273
|
512
|
678
|
|
| Cash from Financing |
-1,971
|
-252
|
-77
|
-24
|
-701
|
-263
|
|
| Stock Issued |
-3,952
|
-252
|
-77
|
-62
|
-17
|
46
|
|
| Debt (LT) Issued |
1,982
|
0
|
0
|
37
|
-41
|
-140
|
|
| Free Cash Flow |
1,398
|
1,503
|
1,970
|
-413
|
430
|
-1,024
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
41.3%
|
32.3%
|
47.5%
|
20.4%
|
18.4%
|
15.5%
|
|
| NCFO / Op.Income |
73.2%
|
110.0%
|
86.6%
|
62.9%
|
111.7%
|
106.3%
|
|
| Current Ratio |
3.6
|
3.7
|
4.5
|
3.8
|
2.6
|
3.6
|
|
| Financial Leverage D/E |
0.24
|
0.06
|
0.08
|
0.11
|
0.11
|
0.10
|
|
| Return on Capital Avg |
29.1%
|
21.7%
|
31.3%
|
11.8%
|
18.8%
|
8.6%
|
|
| Return on Shareholder Equity |
31.8%
|
21.3%
|
32.8%
|
22.6%
|
22.1%
|
20.5%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available